Jim Mazzola
Investor Relations Contact presso OUTSET MEDICAL, INC.
Profilo
Jim Mazzola is Head-Investor Relations for Outset Medical, Inc.
In the past Mr. Mazzola occupied the position of President for CareFusion Foundation, Senior Vice President-Communication at Cardinal Health, Inc., Head-Communication at Halozyme Therapeutics, Inc., Senior Vice President-Corporate Marketing at CareFusion Corp.
and Investor Contact at Turning Point Therapeutics, Inc.
Jim Mazzola received an undergraduate degree and an MBA from the University of Dayton.
Posizioni attive di Jim Mazzola
Società | Posizione | Inizio |
---|---|---|
OUTSET MEDICAL, INC. | Investor Relations Contact | 01/01/2022 |
Precedenti posizioni note di Jim Mazzola
Società | Posizione | Fine |
---|---|---|
CAREFUSION CORPORATION | Investor Relations Contact | 01/03/2015 |
CARDINAL HEALTH, INC. | Public Communications Contact | 01/09/2008 |
CareFusion Foundation | President | - |
HALOZYME THERAPEUTICS, INC. | Investor Relations Contact | - |
TURG POIN | Investor Relations Contact | - |
Formazione di Jim Mazzola
University of Dayton | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
CARDINAL HEALTH, INC. | Distribution Services |
HALOZYME THERAPEUTICS, INC. | Health Technology |
OUTSET MEDICAL, INC. | Health Technology |
Aziende private | 3 |
---|---|
CareFusion Corp.
CareFusion Corp. Medical DistributorsDistribution Services CareFusion Corp. engages in the manufactures of medical equipment and device. The company was founded on February 4, 2009 and is headquartered in San Diego, CA. | Distribution Services |
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
CareFusion Foundation |